Taken together, our results establishJS25 as a therapeutically relevant BTKi, with demonstrated antiproliferativeeffects and improved selectivity profile, and we envisage its clinicaluse against hematological cancers and autoimmune diseases. This evidence concerns the gene IBTK and hematopoietic and lymphoid cell neoplasm.